

## FREEDOM OF INFORMATION REQUEST

RF24-122

We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds part of the information you have requested.

1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)	4
Amivantamab	0
Atezolizumab Monotherapy	3
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel	0
Dabrafenib + Trametinib	1
Docetaxel monotherapy or in combination with Carboplatin/Cisplatin	1
Durvalumab	6
Gemcitabine	0
Nintedanib + Docetaxel	2
Nivolumab	0
Osimertinib	17
Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)	5
Paclitaxel	0
Pembrolizumab Monotherapy	18
Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)	7
Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)	43
Pemetrexed + Platinum (Carboplatin/Cisplatin)	6
RET Inhibitors (Pralsetinib, Selpercatinib)	0
Sotorasib	0
Tepotinib	0
Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin	19
Other active systemic anti-cancer therapy	42
Palliative care only	Unknown*

\*EKHUFT regret we are unable to answer this question as this data is not recorded in ARIA e-prescribing pharmacy system.

2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:

- Atezolizumab monotherapy
- Durvalumab
- Gemcitabine
- Nivolumab
- Osimertinib
- Pembrolizumab (Keytruda) Mono
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)
- Paclitaxel
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin
- Other active systemic anti-cancer therapy (SACT)

- Palliative care only

**EKHUFT regret we are unable to answer this question as this data is not recorded in ARIA prescribing pharmacy system.**

**(DATE OF RESPONSE: 19 FEBRUARY 2024)**